Parathyroid Hormone Regulates Circulating Levels of Sclerostin and FGF23 in a Primary Hyperparathyroidism Model.

Wnt signaling fibroblast growth factor 23 parathyroid hormone protein kinase A sclerostin

Journal

Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997

Informations de publication

Date de publication:
01 Apr 2022
Historique:
received: 12 01 2022
entrez: 14 3 2022
pubmed: 15 3 2022
medline: 15 3 2022
Statut: epublish

Résumé

Parathyroid hormone (PTH) increases fibroblast growth factor 23 (FGF23), mediated both by protein kinase A (PKA) and Wnt signaling, and decreases expression of sclerostin, a Wnt antagonist derived from osteocytes. Patients with primary hyperparathyroidism (PHPT) have lower serum sclerostin levels than healthy controls, consistent with the idea of

Identifiants

pubmed: 35284773
doi: 10.1210/jendso/bvac027
pii: bvac027
pmc: PMC8907412
doi:

Types de publication

Journal Article

Langues

eng

Pagination

bvac027

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society.

Références

Am J Physiol Renal Physiol. 2010 Oct;299(4):F882-9
pubmed: 20685823
Am J Kidney Dis. 2004 Sep;44(3):481-7
pubmed: 15332221
J Bone Miner Res. 2011 May;26(5):1035-46
pubmed: 21140374
J Clin Endocrinol Metab. 2010 Apr;95(4):1991-7
pubmed: 20156921
J Am Soc Nephrol. 2007 Oct;18(10):2683-8
pubmed: 17855636
Calcif Tissue Int. 2013 Apr;92(4):324-9
pubmed: 23430197
Kidney Int. 2016 Jul;90(1):77-89
pubmed: 27165819
PLoS One. 2014 Apr 07;9(4):e93840
pubmed: 24710520
Cell Biol Int. 2018 Sep;42(9):1270-1274
pubmed: 29851201
Genes Dev. 2008 Nov 1;22(21):2968-79
pubmed: 18981475
Mol Endocrinol. 2009 Sep;23(9):1505-18
pubmed: 19556340
J Clin Endocrinol Metab. 2010 Nov;95(11):5056-62
pubmed: 20631014
Endocrinology. 2019 May 1;160(5):1348-1358
pubmed: 30916761
Ther Apher Dial. 2007 Oct;11 Suppl 1:S32-7
pubmed: 17976083
J Bone Miner Res. 2009 Oct;24(10):1681-5
pubmed: 19419295
Wien Med Wochenschr. 2013 Sep;163(17-18):391-6
pubmed: 22805761
J Biol Chem. 1990 Mar 25;265(9):5267-72
pubmed: 2156866
PLoS One. 2008 Aug 13;3(8):e2942
pubmed: 18698360
J Biol Chem. 2005 May 20;280(20):19883-7
pubmed: 15778503
J Biol Chem. 2013 Jul 12;288(28):20122-34
pubmed: 23729679
J Bone Miner Res. 2006 Nov;21(11):1738-49
pubmed: 17002572
Bone. 2017 Mar;96:45-50
pubmed: 27888056
J Clin Invest. 2008 Feb;118(2):722-34
pubmed: 18172553
Endocrinology. 2005 Nov;146(11):4577-83
pubmed: 16081646
Eur J Endocrinol. 2010 Nov;163(5):833-7
pubmed: 20817762
J Mol Histol. 2007 Aug;38(4):261-9
pubmed: 17549589
Bone. 2005 Aug;37(2):148-58
pubmed: 15946907
Bone. 2005 Oct;37(4):589-98
pubmed: 16084134
J Clin Invest. 2008 Dec;118(12):3820-8
pubmed: 19033649
Osteoporos Int. 2012 Jun;23(6):1789-97
pubmed: 22041864
J Biol Chem. 2009 Apr 17;284(16):10890-900
pubmed: 19208630
J Cell Biochem. 2008 May 1;104(1):304-17
pubmed: 17990294
J Clin Invest. 2001 May;107(9):1093-102
pubmed: 11342573
Life Sci. 2006 Apr 11;78(20):2295-301
pubmed: 16337659
Eur J Endocrinol. 2006 Jan;154(1):93-9
pubmed: 16381997

Auteurs

Yuki Nagata (Y)

Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Department of Vascular Medicine, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.
Vascular Science Center for Translational Research, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.

Yasuo Imanishi (Y)

Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.

Tomomi Tateishi (T)

Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.

Daichi Miyaoka (D)

Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.

Masafumi Kurajoh (M)

Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.

Andrew Arnold (A)

Division of Endocrinology and Metabolism, University of Connecticut School of Medicine, Farmington, Connecticut 06032, USA.

Masanori Emoto (M)

Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.

Classifications MeSH